Jamie and Jason Fowler are seeking access to experimental drugs that have not yet been approved by the FDA to treat their son Jack’s life-threatening disease. The pharmaceutical company can make the treatment available to the family without FDA approval, but that could further delay the clinical trials required for official release. “How do we balance the rapid and accelerated approval of drugs that we can establish, definitively establish, are safe and effective,” asks Dr. Russell Medford, who chairs the bioethics committee for the Biotechnology Industry Organization, “versus the immediate needs of individual patients who cannot wait for us to come to those final determinations?” <\/p>\n","protected":false},"excerpt":{"rendered":"